Allworth Financial’s Revolution Medicines RVMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$420K Buy
2,240
+1,556
+227% +$227K ﹤0.01% 1069
2026
Q1
$66.5K Buy
684
+107
+19% +$10.8K ﹤0.01% 2118
2025
Q4
$46K Buy
577
+210
+57% +$13.8K ﹤0.01% 2253
2025
Q3
$17.1K Buy
367
+180
+96% +$7.05K ﹤0.01% 2801
2025
Q2
$6.88K Buy
187
+82
+78% +$3.15K ﹤0.01% 3086
2025
Q1
$4.05K Sell
105
-5
-5% -$203 ﹤0.01% 2876
2024
Q4
$4.5K Buy
110
+14
+15% +$707 ﹤0.01% 2815
2024
Q3
$4.35K Sell
96
-15
-14% -$653 ﹤0.01% 2629
2024
Q2
$5.12K Buy
+111
New +$4.15K ﹤0.01% 2514
2023
Q4
– Sell
-35
Closed -$969 – 3595
2023
Q3
$969 Buy
+35
New +$1.04K ﹤0.01% 2861
2022
Q4
– Sell
-11
Closed – – 3168
2022
Q3
$0 Hold
11
– – ﹤0.01% 3049
2022
Q2
$0 Hold
11
– – ﹤0.01% 2751
2022
Q1
$0 Buy
+11
New +$239 ﹤0.01% 2347
2021
Q4
– Sell
-100
Closed -$3K – 2096
2021
Q3
$3K Hold
100
– – ﹤0.01% 1625
2021
Q2
$3K Hold
100
– – ﹤0.01% 1329
2021
Q1
$5K Hold
100
– – ﹤0.01% 1149
2020
Q4
$4K Hold
100
– – ﹤0.01% 1036
2020
Q3
$3K Buy
+100
New +$2.77K ﹤0.01% 949

Other funds holding RVMD

Allworth Financial's RVMD Position: Q2 2026 in Review

Allworth Financial increased its Revolution Medicines (RVMD) stake by 227% in Q2 2026, buying an estimated $227K and bringing the position to 2,240 shares worth $420K. The position accounts for ﹤0.01% of the portfolio, ranked #1069.

Allworth Financial first reported a position in RVMD in Q3 2020 and has held it in 18 quarters since. 694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Allworth Financial held 2,240 shares of Revolution Medicines worth $420K as of Q2 2026.
  • Allworth Financial bought 1,556 Revolution Medicines shares in Q2 2026, an estimated $227K.
  • Revolution Medicines made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #1069 holding.
  • Allworth Financial first reported a position in Revolution Medicines in Q3 2020 and has held it in 18 quarters since.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.